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Abstract: Coronary and cerebrovascular atherothrombosis are the leading cause of mortality 
and morbidity worldwide. Novel antiplatelet agents have been established for the management 
of patients with clinically evident coronary atherothrombosis and are increasingly used in these 
patients. These agents, however, have shown limited efficacy in the prevention of cerebrovascular 
events and potential harm in patients with history of stroke or transient ischemic attack. Herein, 
the efficacy and safety of two established antiplatelet agents in patients with stroke – aspirin and 
clopidogrel – are reviewed with a focus on the use and challenges related to novel antiplatelet 
agents – prasugrel, ticagrelor, and vorapaxar – in patients at risk for and with a history of stroke 
or transient ischemic attack.
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Introduction
Stroke, a sudden loss of a neurological function due to ischemia or bleeding in the brain, 
is a leading cause of acquired disability and is second only to myocardial infarction as 
the most common cause of death in western countries.1,2 Ischemia, due to the embolic 
or thrombotic occlusion of an intracerebral artery, is the most common etiology of 
stroke (∼80%–90%), while hemorrhagic stroke and subarachnoid hemorrhages are less 
common.3 A history of cerebrovascular accident (CVA; ie, stroke or transient ischemic 
attack [TIA]) in patients with concomitant coronary artery disease increases the risk of 
death, myocardial infarction, or recurrent stroke – both ischemic and hemorrhagic.4–9 
In the Reduction of Atherothrombosis for Continued Health (REACH) registry, a CVA 
that occurred #1 year from enrollment was associated with a risk of recurrent stroke of 
any type that was greater compared with that of a more remote event.4 Anticoagulants 
are established in the management of patients at risk for cardioembolic stroke (eg, 
atrial fibrillation). Antiplatelet agents, such as aspirin and clopidogrel, have reduced 
the incidence of ischemic stroke in patients with known symptomatic cerebrovascular 
disease and in those at high risk for atherothrombosis and are currently used both 
for the management of acute non-cardioembolic ischemic stroke and for secondary 
stroke prevention.10 In the last several years, a number of novel antiplatelet agents 
have emerged in patients with acute and chronic coronary atherothrombosis.11–14 These 
agents, however, have shown limited efficacy and/or potential harm in cerebrovascular 
ischemic events, particularly in patients with  previous CVA. Herein, the efficacy and 
safety of two established antiplatelet agents for the  management of non-cardioembolic 
stroke – aspirin and clopidogrel – are reviewed with a focus on the use and challenges 





related to novel antiplatelet agents – prasugrel, ticagrelor 
and vorapaxar – in patients at risk for and with a history of 
CVA.
Aspirin and clopidogrel
Aspirin has been tested extensively in patients with stroke. 
An irreversible inhibitor of cyclooxygenase-1 that produces a 
permanent defect in thromboxane A
2
-mediated platelet acti-
vation, aspirin is the only agent that has proved beneficial in 
acute stroke. A large trial that tested aspirin (300 mg) started 
within 48 hours after symptom onset showed a nonsignificant 
reduction in mortality (9.0% versus 9.4%) and a significant 
reduction in recurrent ischemic strokes within 14 days (2.8% 
versus 3.9%; P,0.001), a benefit not offset by any signifi-
cant excess in hemorrhagic stroke.15 According to American 
guidelines for the early management of acute stroke, oral 
aspirin (initial dose 325 mg) should be started in most patients 
within 24–48 hours of symptom onset (Class I; Level of 
Evidence A).16 Aspirin is also indicated for secondary stroke 
prevention. A meta-regression analysis of placebo-controlled 
trials of aspirin therapy for secondary stroke prevention 
estimated a 15% (95% confidence interval [CI] 6%–23%) 
 relative risk reduction for stroke of any type (hemorrhagic 
or ischemic).17 According to the American guidelines for the 
prevention of stroke, aspirin (50–325 mg/day) monotherapy 
(Class I; Level of Evidence A) is an acceptable option for 
patients with non-cardioembolic ischemic stroke or TIA.18
Clopidogrel, a second-generation thienopyridine, is 
a prodrug that needs to be metabolized in the liver via 
 cytochrome P450 to produce the active moiety, which pre-
vents adenosine diphosphate-induced platelet activation and 
aggregation by irreversibly inhibiting the P2Y
12
 receptor.19 
Clopidogrel is rapidly absorbed after oral administration with 
peak plasma levels approximately 1 hour after dosing. The 
active metabolite (2-oxo-clopidogrel) is short lived, with a 
half-life of approximately 30 minutes.20
As monotherapy, clopidogrel has been tested for second-
ary stroke prevention in the Clopidogrel Versus Aspirin in 
Patients at Risk of Ischemic Events (CAPRIE) trial (against 
aspirin)21 and the Prevention Regimen for Effectively 
 Avoiding Second Strokes (PRoFESS) trial (against aspirin/
extended release dipyridamole).22 The CAPRIE trial evalu-
ated the efficacy of clopidogrel 75 mg as compared with 
aspirin 325 mg in 19,185 patients with prior myocardial 
infarction, symptomatic peripheral artery disease, or recent 
ischemic stroke (1 week to 6 months before randomization). 
The primary endpoint, a composite of vascular death, myo-
cardial infarction, or ischemic stroke at 1 year, occurred in 
5.3% of patients assigned to clopidogrel as compared with 
5.8% of patients assigned to aspirin with a relative risk 
reduction (RRR) of 8.7% (95% CI 0.3–16.5; P=0.043). In 
the subgroup of patients who qualified for previous stroke, 
the effect of clopidogrel was directionally consistent (RRR 
7.3%, 95% CI 5.7–18.7; P=0.26).21 The PRoFESS trial com-
pared clopidogrel 75 mg daily with the combination of very 
low-dose aspirin (25 mg) plus extended release dipyridamole 
(200 mg) in 20,333 patients with a history of ischemic stroke 
in the previous 90 days. The incidence of recurrent stroke 
of any type during an average follow-up of 2.5 years was 
similar between the two groups (hazard ratio [HR] 1.01, 95% 
CI 0.92–1.11); also, the incidence of ischemic stroke alone 
was similar (HR 0.97, 95% CI 0.88–1.07) but the incidence 
of hemorrhagic stroke was significantly higher in the aspirin 
plus dipyridamole arm (1.4% versus 1.0%, HR 1.42, 95% CI 
1.11–1.83; P=0.006).22
Following the demonstration of clear benefits provided by 
dual antiplatelet therapy (DAPT) with aspirin and clopidogrel 
in patients with acute coronary syndrome (ACS), the Man-
agement of Atherothrombosis with Clopidogrel in High-Risk 
Patients with Recent Transient Ischemic Attacks or Ischemic 
Stroke (MATCH)23 and Clopidogrel for High Atherothrom-
botic Risk and Ischemic Stabilization,  Management, and 
Avoidance (CHARISMA)24 investigators evaluated this 
approach in patients with prior stroke and stable coronary 
artery disease. The MATCH trial randomized 7,599 patients 
with recent TIA or ischemic stroke (within 3 months) to DAPT 
with clopidogrel 75 mg plus aspirin (75 mg) or clopidogrel 
alone (75 mg) and followed them for 18 months. DAPT had 
no significant effect on the  primary endpoint (a composite 
of ischemic stroke, myocardial infarction, vascular death, or 
rehospitalization for an acute ischemic event; RRR 6.4%, 
95% CI −4.6–16.3; P=0.244); or the secondary endpoint 
of ischemic stroke alone (RRR 7.1%, 95% CI −8.5–20.4, 
P=0.35). However, the combination of aspirin and clopidogrel 
increased bleeding compared with clopidogrel alone with a 
1.26% absolute increase in life-threatening bleeding (95% 
CI 0.64–1.88; P,0.0001) and a 0.40% absolute increase in 
symptomatic intracranial hemorrhage (95% CI −0.01–0.82). 
There was no mortality difference.23 The CHARISMA trial 
randomized 15,603 patients with clinically evident cardio-
vascular disease or multiple risk factors for coronary artery 
disease to DAPT with aspirin and clopidogrel or aspirin 
monotherapy. Of the randomized patients, 35% (n=4,320) 
had a history of CVA at baseline. Like MATCH, CHARISMA 
did not show a benefit of DAPT as compared with aspirin 
alone in reducing the incidence of the primary endpoint 
of cardiovascular death, myocardial infarction, or stroke 
(6.8% versus 7.3%, RRR 0.93, 95% CI 0.83–1.05; P=0.22). 




Antiplatelet therapy in patients with prior CVA
The incidence of non-fatal ischemic stroke alone was not 
significantly reduced by DAPT (1.7% versus 2.1%, relative 
risk [RR] 0.81, 95% CI 0.64–1.02; P=0.07). Moderate but 
not severe bleeding according to the Global Utilization of 
Streptokinase and Tissue Plasminogen Activator for Occluded 
Coronary Arteries (GUSTO) definition,25 was increased in 
the combination therapy arm (2.1% versus 1.3%, RR 1.62, 
95% CI 1.27–2.08; P,0.001).24
The use of DAPT with aspirin plus clopidogrel has also 
been studied in a specific subset of ischemic stroke, includ-
ing small artery disease. The Secondary Prevention of Small 
Subcortical Strokes (SPS3) trial randomized 3,020 patients 
with recent (within 6 months) symptomatic small subcortical 
brain infarcts identified by magnetic resonance imaging, also 
known as lacunar strokes. Patients were randomly assigned 
to receive 75 mg of clopidogrel plus aspirin (325 mg/day) 
or aspirin (325 mg/day) alone. The primary outcome was 
 recurrent stroke of any type (ischemic or hemorrhagic). DAPT 
did not reduce the risk of the primary endpoint (125 strokes, 
2.5% per year) as compared with aspirin alone (138 strokes, 
2.7% per year) (HR 0.92, 95% CI 0.72–1.16; P=0.48). 
 However, the risk of major hemorrhage (mostly  systemic) was 
doubled by DAPT (HR 1.97, 95% CI 1.41–2.71; P,0.001). 
 Importantly, DAPT was associated with an unexpected 
increase in all-cause mortality (HR 1.52, 95% CI 1.14–2.04; 
P=0.004) that led to an early termination of the study. These 
findings support the hypothesis that thrombosis may have a 
minimal role in precipitating occlusions of small, penetrat-
ing cerebral arteries,26 which may also explain the low rate 
of recurrent events associated with lacunar strokes.27 It is 
also possible that the use of a relatively high dose (325 mg) 
of aspirin may have contributed to the observed increase in 
bleeding complications.
The only study that showed a possible benefit of DAPT 
in patients with stroke was the Clopidogrel in High-Risk 
Patients with Acute Non-Disabling Cerebrovascular Events 
(CHANCE) trial,28–30 conducted in 5,170 Chinese patients 
randomized within 24 hours of the onset of ischemic minor 
stroke or high-risk TIA to clopidogrel (loading dose of 
300 mg followed by 75 mg/day for 90 days) plus aspirin 
(75–300 mg/day loading dose followed by 75 mg/day for the 
first 21 days) or placebo plus aspirin (75–300 mg  loading 
dose followed by 75 mg/day for 90 days). The primary 
outcome was stroke of any type (ischemic or hemorrhagic) 
at 90 days. The study showed that DAPT, as compared to 
aspirin alone, importantly reduced the incidence of stroke 
(HR 0.68, 95% CI 0.57–0.81; P,0.001) and the composite 
of stroke, myocardial infarction, or vascular death (HR 
0.69, 95% CI 0.58–0.82; P,0.001) (Figure 1). The inci-
dence of  hemorrhagic stroke was similar between the two 
groups (HR 1.01, 95% CI 0.38–2.70; P=0.98).30 Thus, it is 
possible that the combination of the selection of patients 
early after the index event (when recurrence is highest) 
with TIA or a small stroke (associated with a low risk for 
hemorrhagic conversion) and a short duration of therapy 
(21 days) might have hit the “sweet spot” by providing an 
anti-ischemic effect without an increase in bleeding. A 
similar trial, called Platelet-Oriented Inhibition in New TIA 
and Minor Ischemic Stroke (POINT), is currently studying 
these therapies in patients with TIA and minor stroke with 
a narrower time window (treatment within 12 hours after 
symptoms onset).31 A summary of all clopidogrel trials is 
provided in Table 1.
Prasugrel
Prasugrel is a third-generation thienopyridine that is 
more efficiently metabolized compared with clopidogrel, 
thus producing a higher and more predictable level of 
P2Y
12
 inhibition.32,33 Prasugrel was tested against clopi-
dogrel in aspirin-treated patients with ACS and known 
coronary anatomy in the pivotal Trial to Assess Improve-
ment in Therapeutic Outcomes by Optimizing Platelet 
Inhibition with Prasugrel Thrombolysis In Myocardial 
 Infarction 38  (TRITON-TIMI 38). The TRITON-TIMI 
38 trial compared prasugrel (60 mg loading dose and 
10 mg daily maintenance dose) versus clopidogrel 
(300 mg loading dose and 75 mg daily maintenance dose) in 






































Figure 1 Cumulative incidence of survival free of stroke of any type in the 
clopidogrel plus aspirin (red lines) and aspirin (blue lines) groups. 
Notes: Event rates are presented as Kaplan–Meier rate at 90 days and total number 
of events during the trial. From N engl J Med, wang Y, wang Y, Zhao X, et al, 
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack, 369(1), 
11–19. Copyright © 2013 Massachusetts Medical Society. Reprinted with permission 
from Massachusetts Medical Society.30








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Antiplatelet therapy in patients with prior CVA
to receive  percutaneous coronary intervention after diag-
nostic angiography. The primary endpoint was death from 
cardiovascular causes, non-fatal myocardial infarction, 
or non-fatal stroke. The key safety endpoint was major 
bleeding. At 15 months the primary endpoint was signifi-
cantly reduced by prasugrel (HR 0.81, 95% CI 0.73–0.90; 
P,0.001), with an effect that was mostly evident on myo-
cardial infarction and with no effect on stroke (HR 1.02, 
95% CI 0.71–1.45; P=0.93). However, major bleeding was 
increased by prasugrel (2.4% versus 1.8%, HR 1.32, 95% 
CI 1.03–1.68; P=0.03) as well as life-threatening bleeding 
(1.4% versus 0.9%, HR 1.52, 95% CI 1.08–2.13; P=0.01) 
and fatal bleeding (0.4% versus 0.1%, HR 4.19, 95% CI 
1.58–11.11; P=0.002). No clinical benefit and possibly net 
harm was found with prasugrel in patients who qualified 
for prior stroke or TIA at baseline, patients .75 years, 
and those weighing ,60 kg. In particular, patients with 
prior CVA had significant worse clinical outcomes and 
more frequent bleeding (including intracranial bleeding) 
(HR 1.54, 95% CI 1.02–2.32; P=0.04) than those without 
such a history (HR 0.84, 95% CI 0.76–0.93; P,0.001).11 
Notably, the TRITON-TIMI 38 study excluded patients 
with a history of hemorrhagic stroke or an ischemic stroke 
within 3 months of enrollment, a population where the harm 
could have been even higher.34 Prasugrel was also tested 
against clopidogrel in ACS patients managed medically in 
the A Comparison of Prasugrel and Clopidogrel in Acute 
Coronary Syndrome Subjects (TRILOGY) trial, a trial that 
showed a neutral effect for prasugrel35 and that excluded 
patients with prior history of TIA or stroke of any type. 
On the basis of these data, prasugrel is contraindicated in 
patients with a history of stroke of any type or TIA.36
Ticagrelor
Ticagrelor is a first-in-class member of a novel class of oral 
P2Y
12
 inhibitors: the cyclopentyl-triazolo-pyrimidines. Unlike 
thienopyridines, ticagrelor is direct acting (ie, not a prodrug) 
and also reversible with a half-life of 6–12 hours.37,38
In the Platelet Inhibition and Patient Outcomes (PLATO)12 
trial 18,624 patients with ACS were randomized to ticagre-
lor (180 mg loading dose followed by 90 mg twice daily) 
or clopidogrel (300–600 mg loading dose followed by 
 clopidogrel 75 mg once daily) for 12 months. All patients 
received aspirin 75–100 mg daily. The primary endpoint, 
a composite of death from vascular causes, myocardial 
infarction, or stroke at 12 months, occurred in 9.8% of 
patients receiving ticagrelor as compared with 11.7% of 
those receiving clopidogrel (HR 0.84, 95% CI 0.77–0. 92; 
P,0.001) with no significant  difference in the incidence 
of stroke in the two groups (1.5% versus 1.3%, HR 1.17, 
95% CI 0.91–1.52; P=0.22). The rate of death from any 
cause was also reduced with ticagrelor (4.5% versus 5.9% 
with clopidogrel, HR 0.78, 95% CI 0.69–0.89; P,0.001). 
No significant difference in the rates of major bleeding was 
found between ticagrelor and clopidogrel (11.6% versus 
11.2%, HR 1.04, 95% CI 0.95–1.13; P=0.43). However, 
ticagrelor was associated with a higher rate of major bleeding 
not related to coronary artery bypass grafting (4.5% versus 
3.8%, HR 1.19, 95% CI 1.02–1.38; P=0.03), including 
more instances of intracranial bleeding (HR 1.87, 95% CI 
0.98–3.58; P=0.06).12
The effect of ticagrelor in patients with prior CVA was 
evaluated in a post hoc analysis of 1,152 ACS patients in 
PLATO of whom 69 patients had both prior TIA and prior 
stroke, 653 had prior ischemic stroke only, and 430 had 
a prior TIA only. Higher rates of myocardial infarction 
(HR 1.92, 95% CI 1.59–2.33; P,0.0001), death (HR 2.18, 
95% CI 1.79–2.6; P,0.0001), stroke (HR 2.90, 95% 
CI 2.03–4.14; P,0.0001), and intracranial bleeding (HR 
3.95, 95% CI 1.82–8.55; P,0.0005) were observed in 
patients with prior stroke or TIA compared to patients 
with non-CVA history, underscoring the high risk of this 
population. In this subset, ticagrelor, as compared with 
clopidogrel, had an effect that was directionally consistent 
with the overall PLATO trial with no significant interaction 
with the presence of stroke or TIA at baseline. Ticagrelor 
was associated with a nonsignificant reduction in the primary 
endpoint (19.0% versus 20.8%, HR 0.87, 95% CI 0.66–1.13; 
P
int
=0.84) (Figure 2A) with a numerical reduction in mor-
tality (7.9% versus 13.0%, HR 0.62, 95% CI 0.42–0.91; 
P
int
=0.19) (Figure 2B) at 1 year and no significant increase in 
overall major bleeding complications (14.6% versus 14.9%, 
HR 0.99, 95% CI 0.71–1.37; P
int
=0.77) (Figure 2C). Neither 
overall stroke rate (HR 1.13, 95% CI 0.59–2.17; P
int
=0.89) 
nor hemorrhagic stroke rate (HR 0.67, 95% CI 0.11–4.03; 
P
int
=0.25) showed a significant treatment-by-subgroup 
interaction. This analysis therefore indicated that ticagrelor 
had an effect consistent with the overall PLATO results.39 
These results, however, should be balanced with the small 
albeit significant increase in the risk of intracranial bleed-
ing of the drug12 and with a comparator arm (aspirin plus 
clopidogrel) that didn’t provide any ischemic benefit but 
caused increased bleeding compared to either clopidogrel 
or aspirin alone. Therefore, ticagrelor indication needs to be 
more extensively explored in adequately powered clinical 
trials evaluating patients with prior CVA.






Vorapaxar is a selective, orally active, potent, and competitive 
protease-activated receptor 1 antagonist that potently inhibits 
thrombin-induced platelet aggregation. Vorapaxar is rapidly 
absorbed via the oral route and has peculiar pharmacokinet-
ics with a half-life greater than 7 days (159–311 hours). 
It is metabolized and eliminated primarily by biliary and 
gastrointestinal routes.40 Its Phase III program included 
two large trials in patients with acute and chronic coronary 
atherothrombosis, namely Thrombin-Receptor Antagonist 
Vorapaxar in Acute Coronary Syndromes (TRACER)13 and 
Trial to Assess the Effects of SCH 530348 in Preventing 
Heart Attack and Stroke in Patients with Arteriosclerosis 
(TRA 2P-TIMI 50).14
The TRACER trial randomized 12,944 patients with 
ACS without ST-segment elevation to vorapaxar (40 mg 
loading dose followed by 2.5 mg/day) or placebo on top of 
standard of care. The primary endpoint was a composite of 
death from cardiovascular causes, myocardial infarction, 
stroke, recurrent ischemia with rehospitalization, or urgent 
coronary revascularization. The trial was terminated early 













































































































Antiplatelet therapy in patients with prior CVA
major bleeding complication in the vorapaxar arm (HR 1.35, 
95% CI 1.16–1.58; P,0.001), including intracranial hemor-
rhage (HR 3.39, 95% CI 1.78–6.45; P,0.001). In addition, 
vorapaxar did not significantly reduce the primary efficacy 
endpoint (HR 0.92, 95% CI 0.85–1.01; P=0.07) despite a 
promising effect on myocardial infarction (HR 0.88, 95% 
CI 0.79–0.98; P=0.02).13
In the TRA 2P-TIMI 50 trial, vorapaxar (2.5 mg daily) 
was compared to placebo for a median of 30 months in 
26,449 patients who had a history of myocardial infarction, 
ischemic stroke, or peripheral arterial disease. Vorapaxar 
significantly reduced the primary efficacy endpoint (compos-
ite of cardiovascular death, myocardial infarction, stroke, or 
urgent coronary revascularization) compared with placebo 
(HR 0.87, 95% CI 0.80–0.94; P,0.001) and increased 
the risk of moderate to severe bleeding (HR 1.66, 95% 
CI 1.43–1.93; P,0.001), including intracranial hemorrhage 
(HR 1.94, 95% CI 1.39–2.70; P,0.001). After 2 years, the 
data and safety monitoring board recommended discontinua-
tion of the study treatment in patients with a history of stroke 
owing to the risk of intracranial hemorrhage.14 The efficacy 
and safety of vorapaxar in patients with prior ischemic stroke 
was specifically assessed in a subgroup analysis of the TRA 
2P-TIMI 50 which showed that in patients with prior isch-
emic stroke who receive standard antiplatelet therapy, add-
ing vorapaxar increased the risk of intracranial hemorrhage 
without an improvement in major vascular events, including 
ischemic stroke.41
How to use old and new antiplatelet 
agents in patients presenting  
with ACS and with prior stroke?
The development of novel platelet inhibitors for the treatment 
of patients with ACS that showed not only limited efficacy 
but also potential harm in patients with prior stroke repre-
sents a common clinical dilemma for the management of 
patients with both conditions. Optimal management of these 
patients should quantify and individualize the ischemic and 
bleeding risks. In particular, the risk related to the type of 
stroke (minor stroke or TIA, lacunar stroke, cardioembolic 
stroke) and its timing compared to the index ACS4 and the 
risk associated with the ACS event (eg, Global Registry 
of Acute  Coronary Events [GRACE] and Can Rapid Risk 
Stratification of  Unstable Angina Patients Suppress Adverse 
Outcomes with Early Implementation of the  American 
 College of  Cardiology/American Heart  Association 
guidelines  [CRUSADE] risk scores).9,42 Herein are presented 
some general principles to help individualize the selection 
of antiplatelet agent(s), the duration of antiplatelet therapy, 
and also the type of revascularization in this population 
according to the type of presenting ACS, ie, with or without 
persistent ST elevation.
ST elevation ACS
ACS with persistent ST elevation represents a clinical setting 
where the time needed for an adequate patient evaluation and 
therapeutic decision often has to struggle against the need to 
Figure 2 Cumulative incidence of (A) the primary composite of cardiovascular death, myocardial infarction, and stroke; (B) mortality; and (C) major bleeding in the 
ticagrelor (solid lines) and clopidogrel (dotted lines) groups in patients with a history of prior stroke or transient ischemic attack (blue lines) and no previous stroke or 
transient ischemic attack (red lines) at baseline. 
Notes: Event rates are presented as the Kaplan–Meier rate at 360 days and total number of events during the trial.  Reproduced from James SK, Storey RF, Khurmi NS, et al. 
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“save muscle”. In this setting, the time available to collect 
all the information related to the previous cerebrovascular 
event might not be adequate. In this setting it may be useful 
to privilege an approach that allows a short duration of DAPT 
(such as the use of bare-metal stents or second-generation 
drug-eluting stents).43–45 In general, clopidogrel should be 
favored as the adenosine diphosphate-receptor blocker in 
these patients.
Non-ST elevation ACS
In patients with non-ST elevation ACS (ie, non-ST-segment 
myocardial infarction or unstable angina) physicians have 
typically more time to clarify the history of CVA (TIA, 
cardioembolic stroke, lacunar or presumed atherothrombotic 
stroke) and quantify the expected risks and the benefits of 
revascularization (eg, GRACE risk score).42 For example, in 
patients admitted for non-ST-segment myocardial infarction 
with a known history of recent lacunar stroke, long-term 
DAPT therapy post stent implantation would likely increase 
the risk of bleeding and mortality.27 If the expected benefits of 
coronary revascularization (GRACE risk score .140, large 
ischemic area of myocardium) are relevant, DAPT duration 
should be minimized. On the other hand, patients with unsta-
ble angina at low risk might be managed conservatively.
Patients with a history of primary hemorrhagic stroke 
represent a formidable challenge, since most of the above-
mentioned trials excluded these patients. An accurate evalu-
ation of the benefits of revascularization should be balanced 
against the high hemorrhagic risks. Short-duration DAPT or 
monotherapy with clopidogrel may be appropriate according 
to the coronary revascularization strategy (ie, conservative 
or invasive) (Table 1).46,47
Conclusion
The lack of benefit observed with novel antiplatelet agents for 
the prevention of a first or recurrent cerebrovascular event, 
such as prasugrel or vorapaxar (with the possible exception 
of ticagrelor), that proved beneficial for the treatment of 
coronary atherothrombosis underscores the importance of 
carefully weighing the benefit and risk of antiplatelet therapy 
in different clinical settings.
While most trials with combinations of antiplatelet 
agents in patients with prior stroke showed negative results, 
the CHANCE trial indicated that it is still possible to find 
a “sweet spot” where DAPT may be useful.30 However, the 
CHANCE findings may not be necessarily generalizable to 
non-Chinese patients and confirmatory trials in other popula-
tions will be necessary.
Future research is needed to understand the potential 
role of established and novel antiplatelet agents (especially 
ticagrelor), alone or in combinations, and the optimal 
 duration of therapy in the management of patients with 
prior CVA.
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